Variant expands pipeline with InflamaCore inflammasome deal

InflamaCore granted Variant exclusive, worldwide rights to develop and commercialize IC 100 and related products to treat inflammatory diseases. Variant Pharmaceuticals Inc. (Weston, Fla.) also gained rights to develop companion diagnostics for

Read the full 320 word article

How to gain access

Continue reading with a
two-week free trial.